Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
10.1245/s10434-008-9904-3
Annals of Surgical Oncology 15:2293-2300 (2008)
© 2008 Society of Surgical Oncology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Sakashita, K.
Right arrow Articles by Mori, M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sakashita, K.
Right arrow Articles by Mori, M.

Original Article

Clinical Significance of Loss of Fhl1 Expression in Human Gastric Cancer

Katsuya Sakashita, MD1,2, Koshi Mimori, MD, PhD1, Fumiaki Tanaka, MD, PhD1, Yukio Kamohara, MD, PhD1, Hiroshi Inoue, MD, PhD1, Tetsuji Sawada, MD, PhD2, Kosei Hirakawa, MD, PhD2 and Masaki Mori, MD, PhD1

1 Department of Surgery and Molecular Oncology, Medical Institute of Bioregulation, Kyushu University, 4546 Tsurumihara, Beppu 874-0838, Japan
2 Department of Surgical Oncology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan

Correspondence: Address correspondence and reprint requests to: Masaki Mori, MD, PhD; E-mail: mmori{at}tsurumi.beppu.kyushu-u.ac.jp

Background: Human four-and-a-half LIM domains 1 (Fhl1) gene has been reported to achieve cancer suppressive effects. The purpose of this study is to clarify clinical significance of Fhl1 expression in gastric cancer.

Methods: Fhl1 mRNA expression was quantified by real-time reverse transcription (RT)-polymerase chain reaction (PCR) using paired tumor and normal clinical samples from a total of 110 gastric cancer patients. Fhl1 protein expression was investigated by immunohistochemistry. The relationship between Fhl1 mRNA expression and clinicopathological factors was statistically analyzed.

Results: Fhl1 mRNA expression in tumor tissue was significantly downregulated compared with that in normal mucosa (P < 0.0001). Fhl1 protein expression was also diminished in cancer cells by immunohistochemistry. Kaplan–Meier survival curves demonstrated that the patients with low Fhl1 expression tumor showed significantly shorter survival (P < 0.05) than those with high Fhl1 expression tumor. Furthermore, the tumors with low Fhl1 expression showed deeper invasion into the serosal layer (P < 0.05) or more frequent distant metastasis (P < 0.01).

Conclusion: Fhl1 gene was underexpressed in clinical gastric cancer. Loss of Fhl1 expression would be a novel biomarker to determine biological aggressiveness of gastric cancer.

Key Words: Fhl1 • Tumor suppressor • Gastric cancer • Distant metastasis






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the Society of Surgical Oncology.